Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

GKOS
Glaukos Corporation
stock NYSE

At Close
May 8, 2025 3:59:58 PM EDT
90.52USD+2.584%(+2.28)770,897
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 7, 2025 9:15:30 AM EDT
87.67USD-0.646%(-0.57)0
After-hours
May 8, 2025 4:25:30 PM EDT
90.00USD-0.574%(-0.52)1,838
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
04:22PM EST  Analyst Ratings For Glaukos   Benzinga
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022   Benzinga
06:16AM EST  Wells Fargo Upgrades Glaukos to Equal-Weight, Announces $56 Price Target   Benzinga
Jan 18, 2022
10:03AM EST  BTIG Upgrades Glaukos to Buy, Announces $61 Price Target   Benzinga
Jan 12, 2022
08:30AM EST  The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award   Benzinga
05:47AM EST  Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile   Benzinga
Jan 11, 2022
04:13PM EST  Glaukos Announces First Patient Enrolled In Phase 2 Clinical Trial For Presbyopia   Benzinga
04:13PM EST  Glaukos ' iDose TR Demonstrates Sustained IOP Reduction And Favorable Safety Profile Over 36 Months In Phase 2b Study; Says ~70% Of Subjects Were Well-Controlled   Benzinga
04:12PM EST  Glaukos Reports First Patient Enrolled In Phase 2 Trial For Dry Eye Disease   Benzinga
04:10PM EST  Glaukos' iDose(r) TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study   Business Wire
04:10PM EST  Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia   Business Wire
Jan 7, 2022
01:03PM EST  The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs   Benzinga
01:01PM EST  A Peek Into The Markets: US Stock Futures Higher; All Eyes On Jobs Report   Benzinga
Jan 6, 2022
04:13PM EST  Glaukos Announces FDA 510(k) Clearance Of iPRIME   Benzinga
Dec 29, 2021
07:00AM EST  Glaukos Announces Participation in the J.P. Morgan Healthcare Conference   Business Wire
Dec 20, 2021
04:16PM EST  Glaukos Announces Retirement Of William J. Link, Ph.D., As Chairman Of The Board And Election Of Thomas W. Burns As New Chairman   Benzinga
04:15PM EST  Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director   Business Wire
Nov 19, 2021
07:00AM EST  Glaukos Announces Participation in Upcoming Investor Conferences   Business Wire
Nov 11, 2021
07:25AM EST  FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure   Benzinga
07:00AM EST  Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting   Business Wire
Nov 5, 2021
09:46AM EDT  Jefferies Maintains Hold on Glaukos, Raises Price Target to $60   Benzinga
09:26AM EDT  Glaukos Sees FY21 Sales $285M-$290M vs $287.86M Est.   Benzinga
09:26AM EDT  Glaukos Q3 EPS $(0.21) Beats $(0.24) Estimate, Sales $74.70M Beat $72.74M Estimate   Benzinga
Nov 4, 2021
04:10PM EDT  Glaukos Corporation Announces Third Quarter 2021 Financial Results   Business Wire
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 3, 2021
10:23AM EDT  Why Is Glaukos Surging?   RTTNews
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2021   Benzinga
09:14AM EDT  Stephens & Co. Upgrades Glaukos to Overweight, Raises Price Target to $68   Benzinga
06:39AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 06.15 A.M. EDT).   RTTNews
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 14, 2021
07:00AM EDT  Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4   Business Wire
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
04:15PM EDT  Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting   Business Wire
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 22, 2021
05:34AM EDT  Glaukos Corporation Received FDA Orphan Drug Designation on Tuesday for riboflavin 5'-phosphate sodium for Treatment of Corneal Ulcers   Benzinga
Sep 20, 2021
07:09AM EDT  Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc; Attillaps Has Granted Glaukos An Exclusive License To Research, Develop, Manufacture And Commercialize Attillaps' Proprietary Library Of Investigational Pharmaceutical Compounds That Target The Eradication Of Demodex Mites   Benzinga
07:08AM EDT  Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc; Attillaps Has Granted Glaukos An Exclusive License To Research, Develop, Manufacture And Commercialize Attillaps' Proprietary Library Of Investigational Pharmaceutical Compounds That   Benzinga
07:00AM EDT  Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.   Business Wire
Sep 15, 2021
07:07AM EDT  Glaukos Announces Settlement Of Patent Litigation With Ivantis   RTTNews
07:06AM EDT  Glaukos Announces Settlement Of Patent Litigation With Ivantis; Ivantis To Pay $60M And Ongoing Double-Digit Royalty To Glaukos   Benzinga
07:00AM EDT  Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.   Business Wire
Sep 3, 2021
09:45AM EDT  Glaukos Files Pre-Market Application For Intraocular Pressure Device   Benzinga
07:18AM EDT  Glaukos Corp. (GKOS) has submitted a supplemental pre-market approval application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated intraocular pressure in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy.   RTTNews
07:06AM EDT  Glaukos Submits Supplemental Pre-market Approval Application To FDA For IStent Infinite Trabecular Micro-Bypass System   RTTNews
07:02AM EDT  Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite   Benzinga
Sep 1, 2021
11:13AM EDT  Return on Capital Employed Overview: Glaukos   Benzinga
Aug 26, 2021
07:00AM EDT  Glaukos Announces Participation in the Wells Fargo Healthcare Conference   Business Wire
Aug 23, 2021
07:00AM EDT  Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent(r) Technologies   Business Wire
Aug 6, 2021
03:43PM EDT  Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target   Benzinga
07:37AM EDT  Stephens & Co. Maintains Equal-Weight on Glaukos, Lowers Price Target to $60   Benzinga
Aug 5, 2021
04:10PM EDT  Glaukos Corporation Announces Second Quarter 2021 Financial Results   Business Wire
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Jul 26, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021   Benzinga
08:29AM EDT  Stephens & Co. Downgrades Glaukos to Equal-Weight, Announces $70 Price Target   Benzinga
Jul 22, 2021
07:00AM EDT  Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting   Business Wire
Jul 20, 2021
10:14AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021   Benzinga
10:00AM EDT  Shares of Glaukos Corp. (GKOS) are currently slipping nearly 15% despite no stock-related news to drive the shares. The stock has been dropping since last week, when the Centers for Medicare and Medicaid Services (CMS) released new fee schedule for calendar year 2022.   RTTNews
05:51AM EDT  Wells Fargo Downgrades Glaukos to Underweight, Announces $41 Price Target   Benzinga
Jul 14, 2021
02:30PM EDT  Mid-Afternoon Market Update: Dow Gains 50 Points; Imara Shares Plunge   Benzinga
12:07PM EDT  Mid-Day Market Update: Aspen Group Drops Following Q4 Results; Datasea Shares Surge   Benzinga
12:04PM EDT  Oppenheimer Downgrades Glaukos to Perform, Announces $105 Price Target   Benzinga
10:30AM EDT  Mid-Morning Market Update: Markets Open Higher; Citigroup Earnings Beat Expectations   Benzinga
10:05AM EDT  Shares of Glaukos Corp. (GKOS) are slipping nearly 25% on Wednesday's trading after the company commented on the proposed physician fee schedule for 2022.   RTTNews
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021   Benzinga
07:43AM EDT  William Blair Downgrades Glaukos After Disappointing CMS Rate; Shares Drop   Benzinga
07:15AM EDT  William Blair Downgrades Glaukos to Market Perform   Benzinga
02:15AM EDT  Glaukos Says Disappointed With CMS' Proposed 2022 Physician Fees For Category I Codes   RTTNews
02:00AM EDT  Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule   Business Wire
Jun 10, 2021
07:31AM EDT  Glaukos Completes Patient Enrollment And Randomization In NDA Phase 3 Clinical Trials For IDose(r) TR   RTTNews
07:04AM EDT  Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose TR   Benzinga
Jun 8, 2021
07:23AM EDT  Glaukos Announces Australia's TGA Regulatory Approval For PRESERFLO MicroShunt   RTTNews
07:00AM EDT  Glaukos Announces Australia's TGA Regulatory Approval for PRESERFLO(tm) MicroShunt   Business Wire
May 19, 2021
07:00AM EDT  Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference   Business Wire
May 18, 2021
06:00PM EDT  Glaukos Expands its PRESERFLO(tm) MicroShunt Relationship with Santen via New License Agreement   Business Wire
May 5, 2021
04:38PM EDT  Glaukos Sees Q2 Sales $70M-$72M vs $69.56M Est.   Benzinga
04:36PM EDT  Glaukos Q1 Adj. EPS $(0.21) Beats $(0.31) Estimate, Sales $68.00M Beat $65.07M Estimate   Benzinga
04:10PM EDT  Glaukos Corporation Announces First Quarter 2021 Financial Results   Business Wire
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
May 4, 2021
10:34AM EDT  Glaukos's Earnings: A Preview   Benzinga
Apr 27, 2021
07:00AM EDT  Glaukos Announces the Release of its 2020 Sustainability Report   Business Wire
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
07:12AM EDT  Glaukos Announces Global Licensing Agreement Amendment With Intratus, Inc.To Include Treatment Of Presbyopia; Financial Details Not Disclosed   Benzinga
07:00AM EDT  Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia   Business Wire
Apr 14, 2021
04:15PM EDT  Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5   Business Wire
Apr 8, 2021
10:52AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021   Benzinga
09:27AM EDT  Oppenheimer Upgrades Glaukos to Outperform, Raises Price Target to $100   Benzinga
Mar 8, 2021
07:00AM EST  Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives   Business Wire
Mar 3, 2021
07:46AM EST  The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study   Benzinga
Mar 2, 2021
08:01AM EST  The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data   Benzinga
07:00AM EST  Glaukos Announces Participation in Oppenheimer Healthcare Conference   Business Wire
Mar 1, 2021
04:24PM EST  Glaukos Appoints Denice Torres And Leana Wen To Its Board Of Directors   RTTNews
04:10PM EST  Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors   Business Wire
Feb 26, 2021
08:48AM EST  Glaukos' iLink Therapy Meets Primary Endpoint In Late-Stage Vision Disorder Study   Benzinga
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 25, 2021
05:18PM EST  Glaukos Expects Q1 Sales Growth of 15%-20%   Benzinga
05:11PM EST  Glaukos: Q4 Earnings Insights   Benzinga
04:35PM EST  Glaukos Q4 Adj. EPS $(0.02) Beats $(0.29) Estimate, Sales $73.20M Beat $67.84M Estimate   Benzinga
04:27PM EST  Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results   Business Wire
04:05PM EST  Glaukos Announces Positive Phase 3 Trial Results for iLink(tm) Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint   Business Wire
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 24, 2021
10:26AM EST  Earnings Outlook For Glaukos   Benzinga
Feb 10, 2021
07:34AM EST  The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs   Benzinga
Feb 5, 2021
07:44AM EST  The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street   Benzinga
Feb 4, 2021
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
07:00AM EST  Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25   Business Wire
Feb 3, 2021
07:31AM EST  The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision   Benzinga
Jan 29, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021   Benzinga
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
06:09AM EST  Piper Sandler Downgrades Glaukos to Neutral, Raises Price Target to $80   Benzinga
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 13, 2021
07:16AM EST  Glaukos Expects Q4 Net Sales To Be About $73 Mln   RTTNews
07:15AM EST  Glaukos Announces Co.'s iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study; 'Reports 24-Month Average IOP Reductions of 7.9 mmHg and 7.4 mmHg in Fast- and Slow-Release iDose TR Arms, Respectively'   Benzinga
07:13AM EST  Glaukos Says IDose TR Demonstrates Sustained IOP Reduction And Favorable Safety Profile Over 24 Months In Phase 2b Study   RTTNews
07:11AM EST  Glaukos Reports U.S. IDE Trial Results For The Company's iStent infinite Show Substantial Reduction in IOP; Reports 76% of Subjects Achieved 20% or Greater Reduction in Month 12 IOP with Same or Lower Medication Burden   Benzinga
07:10AM EST  Glaukos Sees Q4 Prelim. Sales ~$73M Vs. $67.29M Est., FY20 Prelim. Sales ~$225 Vs. $218.91M Est.   Benzinga
07:00AM EST  U.S. IDE Trial Results for Glaukos' iStent infinite(tm) Show Substantial Reduction in IOP   Business Wire
07:00AM EST  Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales   Business Wire
07:00AM EST  Glaukos' iDose(r) TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study   Business Wire
Jan 8, 2021
07:25AM EST  The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs   Benzinga
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
07:00AM EST  Glaukos Announces Participation in J.P. Morgan Healthcare Conference   Business Wire
Dec 18, 2020
07:48AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data   Benzinga
07:45AM EST  The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data   Benzinga
Dec 16, 2020
08:06AM EST  Citigroup Upgrades Glaukos to Neutral   Benzinga
Dec 9, 2020
09:38AM EST  Benzinga's Top Upgrades, Downgrades For December 9, 2020   Benzinga
05:59AM EST  Oppenheimer Initiates Coverage On Glaukos with Perform Rating, Announces Price Target of $73   Benzinga
Dec 4, 2020
08:04AM EST  The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs   Benzinga
Nov 20, 2020
09:53AM EST  Glaukos Shares Moved Lower; Traders Circulate Piper Sandler Note Stating 'proposed Palmetto LCD for glaucoma drainage devices will not be finalized (the draft LCD appears to have been removed from CMS's site as well)'   Benzinga
Nov 17, 2020
06:36AM EST  Wells Fargo Upgrades Glaukos to Equal-Weight, Announces $68 Price Target   Benzinga
Nov 11, 2020
04:15PM EST  Glaukos Announces Participation in Upcoming Investor Conferences   Business Wire
Nov 5, 2020
05:45PM EST  Glaukos Earlier Reported Q3 EPS $(0.09) Beats $(0.48) Estimate, Sales $64.83M Beat $53.75M Estimate   Benzinga
04:10PM EST  Glaukos Corporation Announces Third Quarter 2020 Financial Results   Business Wire
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Oct 15, 2020
07:00AM EDT  Glaukos Corporation to Release Third Quarter 2020 Financial Results after Market Close on November 5   Business Wire
Oct 8, 2020
10:00AM EDT  Benzinga's Top Upgrades, Downgrades For October 8, 2020   Benzinga
06:43AM EDT  JP Morgan Downgrades Glaukos to Underweight, Announces $50 Price Target   Benzinga
Sep 9, 2020
09:48AM EDT  INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the Firm   Business Wire
Sep 4, 2020
07:00AM EDT  Glaukos Announces Participation in September Investor Conferences   Business Wire
Aug 18, 2020
05:49PM EDT  Avedro; Avedro Investors Receiving Glaukos Shares Encouraged to Contact Johnson Fistel   PR Newswire
Aug 6, 2020
05:04PM EDT  Glaukos Q2 Adj. EPS $(0.61) Beats $(0.76) Estimate, Sales $31.60M Beat $20.06M Estimate   Benzinga
04:10PM EDT  Glaukos Corporation Announces Second Quarter 2020 Financial Results   Business Wire
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Jul 20, 2020
07:00AM EDT  Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC